Collaborative Arrangements (Tables)

12 Months Ended

Dec. 31, 2012

Collaborative Arrangements

Collaborator revenues

During the three years ended December 31, 2012, the Company recognized the following revenues attributable to the Janssen collaboration:

	2012			2011			2010
	(in thousands)
Royalty revenues	$	117,592		$	20,289		$	—
Collaborative revenues:
Amortized portion of up-front payment	$	12,428		$	12,428		$	12,428
Milestone revenues	—			250,000			—
Net reimbursement (payment) for telaprevir development costs	(3,507		)	(8,418		)	9,245
Reimbursement for manufacturing services	7,257			20,383			9,077
Total collaborative revenues attributable to the Janssen collaboration	$	16,178		$	274,393		$	30,750
Total revenues attributable to the Janssen collaboration	$	133,770		$	294,682		$	30,750

During the three years ended December 31, 2012, the Company recognized the following collaborative revenues attributable to the Mitsubishi Tanabe collaboration:

	2012		2011		2010
	(in thousands)
Amortized portion of up-front payments	$	12,744	$	38,232	$	38,232
Milestone revenues	485		68,515		—
Payments for manufacturing services	5,650		14,928		43,636
Total collaborative revenues attributable to the Mitsubishi Tanabe collaboration	$	18,879	$	121,675	$	81,868

Summary of activity related to net loss (income) attributable to noncontrolling interest (Alios)

A summary of net loss (income) attributable to noncontrolling interest (Alios) for the two years ended December 31, 2012 is as follows:

	2012			2011
	(in thousands)
Loss (income) before provision for (benefit from) income taxes	$	20,044		$	9,536
Decrease (increase) in fair value of contingent milestone and royalty payments	(114,970		)	(69,950		)
Provision for (benefit from) income taxes	39,029			48,809
Net loss (income) attributable to noncontrolling interest (Alios)	$	(55,897	)	$	(11,605	)

Summary of Alios' items included in the Company's consolidated balance sheets

Alios Balance Sheet Information

The following table summarizes items related to Alios included in the Company’s consolidated balance sheets:

	As of December 31,
	2012		2011
	(in thousands)
Restricted cash and cash equivalents (Alios)	$	69,983	$	51,878
Prepaid expenses and other current assets	672		2,299
Property and equipment, net	1,728		1,925
Intangible assets	250,600		250,600
Goodwill	4,890		4,890
Other assets	861		133
Accounts payable	1,054		4,132
Accrued expenses	6,099		4,304
Income taxes payable (Alios)	715		12,075
Deferred tax liability	152,781		116,121
Other liabilities, excluding current portion	910		1,030
Redeemable noncontrolling interest (Alios)	38,530		37,036
Noncontrolling interest (Alios)	196,672		141,633

The Company has recorded Alios’ cash and cash equivalents as restricted cash and cash equivalents (Alios) because (i) the Company does not have any interest in or control over Alios’ cash and cash equivalents and (ii) the Alios Agreement does not provide for these assets to be used for the development of the assets that the Company licensed from Alios pursuant to the Alios Agreement. Assets recorded as a result of consolidating Alios’ financial condition into the Company’s consolidated balance sheets do not represent additional assets that could be used to satisfy claims against the Company’s general assets.